Stock Events

Stock Events

Corvus Pharmaceuticals 

$17.14
48
+$1.6+10.3% Tuesday 20:00

Statistics

Day High
17.28
Day Low
15.56
52W High
25.52
52W Low
3.2
Volume
1,465,535
Avg. Volume
-
Mkt Cap
1.28B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.6
-0.42
-0.25
-0.07
Expected EPS
-0.147125
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-124.59MNet Income

Analyst Ratings

34Average Price Target
The highest estimate is 42.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRVS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol Myers Squibb competes in the oncology segment, developing treatments that overlap with Corvus Pharmaceuticals' focus on cancer immunotherapy.
Merck
MRK
Mkt Cap294.39B
Merck is a leading pharmaceutical company with a strong presence in cancer treatment, directly competing with Corvus in the immunotherapy space.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences has a significant focus on oncology and immuno-oncology, areas where Corvus Pharmaceuticals is actively developing therapies.
Astrazeneca
AZN
Mkt Cap317.5B
AstraZeneca operates in various therapeutic areas, including cancer, where its development of immunotherapies competes with Corvus' pipeline.
Pfizer
PFE
Mkt Cap156.77B
Pfizer has a broad portfolio that includes oncology, competing with Corvus Pharmaceuticals in the development of cancer treatments.
Novartis
NVS
Mkt Cap293.34B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, making it a direct competitor to Corvus.
Roche
RHHBY
Mkt Cap330.22B
Roche, through its Genentech division, is a leader in biotechnology focusing on oncology, which competes with Corvus Pharmaceuticals' focus areas.
AMGEN
AMGN
Mkt Cap191.53B
Amgen focuses on human therapeutics, including oncology and hematology, areas where Corvus is seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals is involved in the discovery and development of pharmaceutical products for the treatment of serious medical conditions, including cancer, competing with Corvus.
Incyte
INCY
Mkt Cap19.47B
Incyte Corporation specializes in oncology products, directly competing with Corvus Pharmaceuticals in the development of cancer therapies.

About

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Show more...
CEO
Dr. Richard A. Miller M.D.
Employees
31
Country
United States
ISIN
US2210151005

Listings

STU
DE
C17.STU
MU
DE
C17.MU
XNAS
US
CRVS
F
DE
C17.F

0 Comments

Share your thoughts

FAQ

What is Corvus Pharmaceuticals stock price today?▼
The current price of CRVS is $17.14 USD — it has increased by +10.3% in the past 24 hours. Watch Corvus Pharmaceuticals stock price performance more closely on the chart.
What is Corvus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corvus Pharmaceuticals stocks are traded under the ticker CRVS.
Is Corvus Pharmaceuticals stock price growing?▼
CRVS stock has risen by +13.74% compared to the previous week, the month change is a +28.58% rise, over the last year Corvus Pharmaceuticals has showed a +414.71% increase.
What is Corvus Pharmaceuticals market cap?▼
Today Corvus Pharmaceuticals has the market capitalization of 1.28B
When is the next Corvus Pharmaceuticals earnings date?▼
Corvus Pharmaceuticals is going to release the next earnings report on May 11, 2026.
What were Corvus Pharmaceuticals earnings last quarter?▼
CRVS earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.13 USD resulting in a -15.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corvus Pharmaceuticals revenue for the last year?▼
Corvus Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Corvus Pharmaceuticals net income for the last year?▼
CRVS net income for the last year is -124.59M USD.
How many employees does Corvus Pharmaceuticals have?▼
As of April 22, 2026, the company has 31 employees.
In which sector is Corvus Pharmaceuticals located?▼
Corvus Pharmaceuticals operates in the Health & Wellness sector.
When did Corvus Pharmaceuticals complete a stock split?▼
Corvus Pharmaceuticals has not had any recent stock splits.
Where is Corvus Pharmaceuticals headquartered?▼
Corvus Pharmaceuticals is headquartered in South San Francisco, United States.